European Psychiatry - Volume 33 - March 2016

685 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S681
similarly, opening a new line of research and treatment of condi-
tions with these characteristics.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1038
The role of long-acting antipsychotic
treatment in schizophrenia with
comorbid drug use. The case of
paliperidone palmitate
A. Portilla Fernández , L. Reula , E. Manrique Astiz ,
L.A. Nú˜nez Domínguez ∗, O. Arbeo Ruiz , M. García Nicolás ,
O. Fernández de la Vega
1 Clíncia de Rehabilitación, Psychiatry, Pamplona/Iru˜na, Spain
2 Hospital de Día, Psychiatry, Pamplona/Iru˜na, Spain
3 Mental Health Center, Psychiatry, Tafalla, Spain
4 Centro Médico, Psychiatry, Pamplona, Spain
5 Centro de Día Zuría, Psychiatry, Pamplona/Iru˜na, Spain
6 Mental Health Center, Psychiatry, Tudela, Spain
7 Mental Health Center, Psychiatry, Pamplona/Iru˜na, Spain
∗ Corresponding author.
The patient suffering a schizophrenic disorder with a comorbid
drug use is a challenge for the technical team of psychiatrists who
provide to control this disorder. In some guides that include a
revision of the efficacy of several psychopharmacological and/or
psychological treatment shows that there any treatment has no
efficacy in this group of patients. But it suggests that long-acting
antipsychotic may play a role in some cases with no adherence.
We study prospectively some data in a group of patients of these
characteristics treated with paliperidone palmitate as main psy-
chopharmacological treatment, using asmeasurements of outcome
the number of psychiatric admissions, dosage of oral treatment, use
of drug before and after the beginning of Paliperdione Palmitate.
Our results show that it exists a decrease of number of admissions,
dosage of oral concomitant treatment and drug use, with a very
good adherence and no dropouts in the follow-up. We conclude
that Paliperidone Palmitate may be a very good alternative for the
psychopharmacological treatment in schizophrenic patients with
comorbid drug use.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1039
Heavy cannabis use impairs verbal
memory of first psychotic episode
patients
C. Nu˜nez , S. Ochoa , E. Huerta-Ramos , I. Ba˜nos , A. Barajas ,
M. Dolz , B. Sanchez , N. Del Cacho , G. Genipe , J. Usall ∗
1 Parc Sanitari Sant Joan de Déu, CIBERSAM, Research Unit, Sant Boi
de Llobregat, Spain
2 Parc Sanitari Sant Joan de Deu, CIBERSAM, Research Unit, Sant Boi
de Llobregat, Spain
3 Centre d’ Higiene Mental Les Corts, Research Unit, Barcelona, Spain
4 Hospital Materno Infantil Sant Joan de Déu- Esplugues, Psychiatry
Department, Esplugues de Llobregat, Spain
5 Hospital Materno Infantil Sant Joan de Déu, Psychiatry Department,
Esplugues de Llobregat, Spain
6 Parc Sanitari Sant Joan de Déu, Research Unit, Sant Boi de Llobregat,
Spain
7 Parc Sanitari Sant Joan de Déu, Psychiatry Research, Sant Boi de
Llobregat, Spain
∗ Corresponding author.
Introduction Cannabis consumption is known to be increased
in both schizophrenic and first psychotic episode patients. Con-
trary to what has been reported in studies with healthy people,
all published studies so far have reported no impairments or even
beneficial effects on neurocognition associated with cannabis con-
sumption in schizophrenia and first psychotic episode patients.
However, these studies did not address the effects of very high
cannabis consumption.
Objective Our aim in this study was to assess the effects on neu-
rocognition of regular and heavy cannabis consumption in first
psychotic episode patients.
Methods A total of 74 patients were included in the study and
assigned to 3 different groups according to their mean cannabis
consumption during the last year (non-users, regular users, and
heavy users). Participants were administered verbal memory,
attention, processing speed, working memory, vocabulary, arith-
metic and spatial orientation tasks.
Results Our results showed the heavy cannabis group of first psy-
chotic episode patients to be significantly impaired in all the verbal
memorymeasures with respect to the non-users group. There were
no significant differences between regular users and non-users.
Moreover, regular cannabis consumption was associated with an
improvement in some attention and processing speed measures.
Conclusions Our data showed heavy cannabis consumption to
impair verbal memory in first psychotic episode patients and sug-
gest a dose-related effect of cannabis consumption, since regular
consumption did not impair verbal memory and may be beneficial
for other tasks.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1040
Choosing an antipsychotic on a case of
late-onset psychosis – A challenge on
everyday practice
M. Oliveira∗ J. Peixoto , C. Novais , C. Santos
Centro Hospitalar São João, EPE, Psychiatry and Mental Health Clinic,
Porto, Portugal
∗ Corresponding author.
Introduction Psychosis with onset in late adulthood already con-
stitutes a challenge on the differential diagnosis and treatment,
especially in polypharmacy patients.
Methods and aims We present a case report of a 61-year old
woman with a late-onset psychosis and discuss the clinical evo-
lution and the pharmacological treatment.
Results The patient suffered from obesity, type II diabetes melli-
tus with poor glycemic control, and hypertension. She had a first
psychotic episode at the age of 56, having persecutory delusional
ideas and auditory hallucinations with psychomotor agitation and
insomnia. She was first medicated with an atypical antipsychotic
(olanzapine) with little response and worsening of the glycemic
control. A switch was performed to haloperidol with remission of
symptomatology with low doses (4mg/day). Through follow-up
the doses of haloperidol was decreased and eventually suspended,
but having a relapse a few months later. Haloperidol was again
introduced and the symptoms remitted. Stability was maintained,
but the patient started to show lower limbs symmetrical rigidity
and psychomotor retardation. It was decided to switch haloperidol
to risperidone, but the patient reported side effects with its use,
and had to stop it. Haloperidol was again introduced, but had to be
discontinued after motor symptoms got worse. Again the patient
had another recurrence of psychotic symptoms and it was decided
to introduce paliperidone (6mg/day) with good response and tol-
erability.
Conclusions The safety and tolerability of antipsychotic medi-
cation is variable. When choosing a treatment in a patient with